Nucleic Acid Based Multiplex Assays Market Report 2025 (Global Edition)

Global Nucleic Acid Based Multiplex Assays Market Report 2025 Market Size Split by Application (Companion Diagnostics, Clinical Diagnostics, Research and Development ), by Product Type (Reagents and...

Nucleic Acid Based Multiplex Assays Market Report Description

We have various report editions of Nucleic Acid Based Multiplex Assays Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Nucleic Acid-Based Multiplex Assays Market

The competitive environment in the nucleic acid multiplex assay industry is dynamic and ever-changing. A plethora of entities, ranging from established industry titans to innovative startups, contend for domination and market share. Tough competition fosters a continuous quest for innovation and outstanding performance as businesses aim to set themselves apart via better product quality, pricing strategies, and customer happiness. Variables, including new developments in technology, changes in regulations, and shifting customer tastes, all influence market dynamics. In addition to pushing market expansion, this dynamic rivalry presents opportunities and challenges for players, encouraging strategic alliances, mergers, and acquisitions as companies try to stay ahead of the curve in this ever-changing landscape. In general, there is a fascinating variety of rivalry in the nucleic acid multiplex assay market.

Nucleic Acid-Based Multiplex Assays Industry News 

In November 2023, Gilead Sciences worked with DiaSorin S.p.A. The development of a completely automated diagnostic assay for the hepatitis delta virus was the outcome of this partnership.

(Source: https://int.diasorin.com/sites/default/files/press-releases/PR%20Diasorin%20-%20Gilead%20HDV%20Development_ENG.pdf)

Top Companies Market Share in Nucleic Acid Based Multiplex Assays Industry: (In no particular order of Rank)

• Abbott Laboratories
• Roche Diagnostics
• Illumina
• Thermo Fisher Scientific
• Agilent Technologies
• Bio-Rad Laboratories
• Qiagen
• Danaher Corporation
• Shimadzu Biotech
• Siemens Healthineers
• Protavio
• Merck
• Luminex Corporation
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of Nucleic Acid-Based Multiplex Assays

Which Region will dominate the Nucleic Acid-Based Multiplex Assays Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. Additionally, a significant factor propelling market expansion is the high burden of infections and tumors on local healthcare systems. Additional factors expected to help the market's growth in the region include the existence of a sophisticated healthcare infrastructure and the increasing uptake of cutting-edge technology for infectious disease and cancer diagnosis. Spending on healthcare has grown significantly in North America over time. Another more significant factor propelling the biotechnology industry is the rising cost of healthcare.

Which is Expanding at the Fastest CAGR?

Asia-Pacific is the fastest growing country because of its large and growing population with rising disposable incomes, growing public expenses on healthcare infrastructure, growing understanding of early disease detection and individualized treatments, and increasing prevalence of infectious diseases and chronic illnesses like cancer. There is also a sizable and expanding elderly population in the APAC area. Chronic illnesses like diabetes, heart disease, and cancer are more common in this population. Multiplex assays based on nucleic acids can be utilized to identify these illnesses early on when they are most amenable to treatment.

The current report Scope analyzes Nucleic Acid Based Multiplex Assays Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Nucleic Acid Based Multiplex Assays Market

According to Cognitive Market Research, the global nucleic acid-based multiplex assays market size was estimated at USD XX Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD xx million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031. The necessity for quick and precise diagnostic testing has been brought to light by the current COVID-19 outbreak. Multiple pathogens can be found in a single sample using nucleic acid-based multiplex assays, which expedites and reduces the need for resources for detecting infectious diseases. Personalized medicine bases a patient's course of care on their particular genetic composition. More specialized treatments are made possible by the ability to discover genetic alterations linked to a variety of diseases using multiplex assays based on nucleic acids. North America boasts a highly developed healthcare infrastructure characterized by a large concentration of hospitals and research facilities. The adoption of new technologies, such as multiplex tests based on nucleic acids, is facilitated by this infrastructure.

• According to Cognitive Market Research, the US had a major share in the nucleic acid-based multiplex assays market with a market size of USD xx million in 2024 and is projected to grow at a CAGR of 7.7% during the forecast period. Within the global market, the US market for nucleic acid-based multiplex assays is a strong and expanding segment. 
• The Canada nucleic acid-based multiplex assays market had a market share of USD xx million in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period. The Canadian government prioritizes universal healthcare access, leading to a supportive environment for the adoption of advanced diagnostics. The growing elderly population in Canada increases the demand for diagnostic tests, including multiplex assays for early disease detection and management, and is also involved in precision medicine infrastructure.

• The Mexico nucleic acid-based multiplex assays market is projected to grow at a CAGR of 8.4% during the forecast period, with a market size of USD XX million in 2024. 

 

Europe Nucleic Acid Based Multiplex Assays Market

According to Cognitive Market Research, with a market value of USD XX million in 2024, it is projected to expand at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031. Europe accounted for a share of over 30% of the global market size of USD XX million. Europe's governments are realizing more and more how multiplex tests might enhance patient care. They are thus sponsoring research and development of novel multiplex tests as well as the implementation of these assays in clinical settings. New multiplex assay technologies that are more economical, precise, and sensitive are constantly being developed. Multiplex assays are becoming increasingly appealing to a larger group of consumers in Europe as a result of these developments. In Europe, the prevalence of chronic illnesses like cancer, infectious disorders, and autoimmune diseases is rising. Better patient outcomes may result from the early diagnosis and tracking of certain disorders with multiplex tests.

• The United Kingdom nucleic acid-based multiplex assays market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 9.0% during the forecast period. One of the largest markets in Europe for nucleic acid-based multiplex tests is the UK, which is also home to several top producers of these products.

• The French nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 7.4% during the forecast period, with a market size of USD XX million in 2024.
• According to Cognitive Market Research, the market size of the German nucleic acid-based multiplex assays was valued at USD XX million in 2024 and is projected to grow at a CAGR of 8.4% during the forecast period. Germany has a growing aging population, which is leading to an increase in chronic diseases such as cancer and diabetes. Multiplex assays can be used to diagnose these diseases at an early stage when treatment is most effective.
• The Italy nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD xx million in 2024.
• The Russia nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD XX million in 2024.
• The Spain nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD XX million in 2024.
• The Luxembourg nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 8.3% during the forecast period, with a market size of USD XX million in 2024.
• The Portugal nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD XX million in 2024.
• The Greece nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD million in 2024.
• The rest of the Europe nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 6.9% during the forecast period, with a market size of USD XX million in 2024.

Asia Pacific Nucleic Acid Based Multiplex Assays Market

According to Cognitive Market Research, the global nucleic acid-based multiplex assays market size was estimated at USD XX Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2024 to 2031. The region of Asia-Pacific is anticipated to expand at the fastest rate during the projection period due to a rise in the number of people with infectious and chronic illnesses, increased consumer awareness of multiplex assay products and services, and rising purchasing power of densely populated nations like China and India. The population of the Asia Pacific area is sizable and expanding, and it is becoming more vulnerable to infectious diseases. Antibiotic resistance, globalization, and urbanization are some of the causes of this. Multiplex tests based on nucleic acids provide a quick and precise way to identify infectious diseases, which can aid in limiting their spread.

• According to Cognitive Market Research, the market size of China's nucleic acid-based multiplex assays was valued at USD XX million in 2024 and is projected to grow at a CAGR of 11.2% during the forecast period. The market for nucleic acid-based multiplex assays in the Asia Pacific region is growing mostly due to China. There are a number of reasons why the market is anticipated to develop significantly. The increasing demand for personalized medicine, the rising incidence of chronic diseases, and the growing government support for healthcare are some of the key factors that are driving the growth of the market.

• The Japan nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD XX million in 2024. 
•  The India nucleic acid-based multiplex assays market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 13.5% during the forecast period. In the upcoming years, it is anticipated that the Indian market for multiplex assays based on nucleic acids will expand quickly. The increased burden of infectious and chronic illnesses, growing public knowledge of the advantages of multiplex assays, and government backing for the adoption of novel diagnostic technologies will all contribute to this growth.
• The South Korean nucleic acid-based multiplex assay market is projected to witness growth at a CAGR of 10.8% during the forecast period, with a market size of USD XX million in 2024.
• The Australian nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 11.4% during the forecast period, with a market size of USD XX million in 2024.
• The Southeast Asia nucleic acid multiplex assay market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of the Asia Pacific nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 11.5% during the forecast period, with a market size of USD xx million in 2024.

 

South America Nucleic Acid Based Multiplex Assays Market

According to Cognitive Market Research, the global nucleic acid-based multiplex assays market size was estimated at USD XX Million, out of which the Latin America market of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. HIV/AIDS, TB, and dengue fever are among the many infectious diseases that are prevalent throughout Latin America. Rapid and precise diagnosis of many illnesses is possible with multiplex tests, which can enhance patient outcomes and stop the spread of illness. An approach to treatment known as "personalized medicine" considers the variations in each person's genes, environment, and lifestyle. Using multiplex tests, one can determine genetic variants that may influence an individual's susceptibility to specific diseases. Treatment plans that are specific to each patient can be created using this data. Latin American governments are spending more money on healthcare, which is encouraging the use of modern technology like multiplex tests.

• According to Cognitive Market Research, the market size of Brazil's nucleic acid-based multiplex assays was valued at USD XX million in 2024 and is projected to grow at a CAGR of 9.7% during the forecast period. Brazil's expanding population, increasing prevalence of chronic illnesses, and increased government spending on healthcare have made it one of the region's biggest marketplaces.

• The Argentina nucleic acid-based multiplex assays market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 10.0% during the forecast period. Argentina has made a noteworthy contribution. The main forces are the increasing prevalence of disease, improving understanding of individualized therapy, and technology developments. However, issues like excessive expenses and a lack of qualified workers must be resolved to ensure further growth.
• The Colombia nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 8.9% during the forecast period, with a market size of USD XX million in 2024.
• The Peru nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD XX Million in 2024.
• The Chile nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 9.4% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of the Latin American nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD XX million in 2024.

 

Middle East and Africa Nucleic Acid Based Multiplex Assays Market

According to Cognitive Market Research, the global nucleic acid-based multiplex assays market size was estimated at USD XX Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031. The MEA market for multiplex assays based on nucleic acids would expand at a considerable rate. The main forces behind this rise are the rising prevalence of infectious diseases, the expanding understanding of personalized therapy, and the advancement of healthcare infrastructure. Infectious diseases, including HIV/AIDS, TB, and malaria, are highly prevalent in the MEA region. Patient outcomes may be enhanced by the rapid and precise diagnosis of various illnesses made possible by multiplex tests. The MEA region has a large number of nations with inadequate healthcare systems. Because several diseases can be diagnosed with a single test thanks to multiplex assays, time and money can be saved.

• According to Cognitive Market Research, the GCC Countries' nucleic acid-based multiplex assays market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 10.2% during the forecast period. GCC governments are increasing their spending on healthcare infrastructure and services.
• The Egypt nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD XX million in 2024.

• The South African nucleic acid-based multiplex assay market is projected to witness growth at a CAGR of 10.4% during the forecast period, with a market size of USD XX million in 2024. 
• The Turkish nucleic acid-based multiplex assay market is projected to witness growth at a CAGR of 8.9% during the forecast period, with a market size of USD XX million in 2024.
• The Nigeria nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of the MEA nucleic acid-based multiplex assays market is projected to witness growth at a CAGR of 8.4% during the forecast period, with a market size of USD million in 2024.

Nucleic Acid Based Multiplex Assays Market Analysis

Nucleic Acid-Based Multiplex Assays Application Segment Analysis

According to Cognitive Market, research and development held the major market share over the forecast period. Throughout the projected period, research & development is anticipated to continue to hold the top spot in the market. This can be attributed to the increasing use of multiplex assays in academic research as well as medication discovery and development. The research and development of nucleic acid-based multiplex assays is a rapidly growing field. New technologies are constantly being developed to improve the accuracy, sensitivity, and specificity of these assays.

Clinical Diagnostics is the fastest-growing category over the forecast period. The market for nucleic acid-based multiplex assays is anticipated to grow at the quickest rate in the clinical diagnostics application sector. The variables above, as well as the growing use of point-of-care (POC) testing, are responsible for this development. Rapid and decentralized diagnoses are made possible by POC testing, which is crucial in environments with limited resources.

• Companion Diagnostics
• Clinical Diagnostics
• Research and Development 

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Nucleic Acid Based Multiplex Assays Industry. Request a Free Sample PDF!

Nucleic Acid-Based Multiplex Assays Product Type Segment Analysis

According to Cognitive Market Research, reagents & consumables hold a prominent market share. Because of the widespread use of consumables and reagents and the regular acquisition of assays and reagents for expanding research applications. This section contains the primers, probes, buffers, enzymes, and other materials needed for multiplex tests. This market is expanding due to the widespread use of multiplex assays in many applications.

Software and Services is the fastest-growing category over the forecast period. This is because cloud-based solutions for multiplex assay data management are becoming increasingly popular, and there is a growing need for services related to data processing and interpretation. Due to the considerations above, the market for nucleic acid-based multiplex tests is anticipated to increase significantly over the next several years. The increasing demand for data analysis and management solutions is an opportunity for the software and services market to profit from this expansion.

• Reagents and Consumables
• Instruments and Accessories
• Software and Services

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Nucleic Acid Based Multiplex Assays End-User Segment Analysis

According to Cognitive Market Research, hospitals hold a prominent market share. Traditional single-analyte tests can take substantially longer to produce findings than multiplex assays. In hospital settings, prompt diagnosis is essential to patient care, hence this is vital. Hospitals are using multiplex assays for a growing number of purposes, such as pharmacogenomics, cancer diagnosis, and testing for infectious diseases.

Pharmaceutical and Biotechnology Companies are the fastest-growing category over the forecast period. In the process of finding and developing new drugs, multiplex assays are utilized to confirm new targets. In order to comprehend how genes are regulated in health and sickness, they are also utilized in research on gene expression. Pharmaceutical and biotechnology companies are investing heavily in R&D to develop new and improved multiplex assays. This includes developing assays that can detect a larger number of targets with higher sensitivity and specificity.

• Hospitals
• Clinical Laboratories
• Research Institutes
• Pharmaceutical and Biotechnology Companies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion